Designed to balance blood sugar levels in patients with type 2 diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists gained fame through a distinct and significant side effect: weight loss
Pharmaceuticals (MDPI) (2025) 6
Industry Growth Overview: The Oral GLP-1 therapy landscape has seen significant advancements in 2025, focusing on improved bioavailability, enhanced efficacy, and patient convenience
Primary Handling Editor: Ming Yang, in collaboration with the Nature Medicine team
Nauck M, Weinstock RS, Umpierrez GE, et al
For enrichment analysis, isotopically labeled glucose ( 13 C 6 glucose), acetate ( 13 C 2 acetate), or palmitate ( 13 C 16 palmitate) was added to culture media and the enrichment into acyl-CoAs was determined using FluxFix based on samples treated with no isotope tracer 48